George Azevedo de Oliveira

George Azevedo de Oliveira

Auto-generated profile, based on publicly available information

George Azevedo de Oliveira

Laboratório de Bioinformática e Química Medicinal, Fundação Oswaldo Cruz, CEP: 76812-245 Porto Velho-RO, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2020 in International Journal of Food Science and Technology
Verified
Journal Article
Closed access
PDF file
AFAnna Beatriz Sabino Ferrari
Anna Beatriz Sabino Ferrari
GOGeorge Azevedo de Oliveira
George Azevedo de Oliveira
HRHelena Mannochio Russo
Helena Mannochio Russo
LBLuiza Bertozo
Luiza Bertozo
VBVanderlan Bolzani
Vanderlan Bolzani
MZMaria Luiza Zeraik
Maria Luiza Zeraik
In this study, the chemical composition, total phenolic content, and antioxidant activity (DPPH, ORAC and FRAP assays) of A. subrufescens and P. ostreatus , cultivated with handmade and commercials supplements, were compared. Additionally, the compounds ergosterol, saccharopine, and hexitol were identified in A. subrufescens by HPLC‐MS/MS. The antioxidant compound p ‐coumaric acid and dihexoses were found in both mushroom species. A. subrufescens presented higher total phenolic content (73.8±0.6 mg GAE 100 g‐1) and antioxidant activity than P. ostreatus (16.6±0.5 mg GAE 100 g‐1). The handmade supplement based on the waste of noble grains presented statistically similar phenolic content to the mushrooms cultivated with commercial ones Spawn Mate II SE (86.1±1.4 and 92.9±0.3 mg GAE 100 g‐1, respectively). Therefore, the results support the use of handmade supplements base on agro‐wastes as a viable alternative to the use of high‐cost commercial ones.

13 May 2024 in ACS Omega
Verified
Journal Article
Open access
GOGeorge A R Oliveira
George A R Oliveira
BMBruno G D V Morales
Bruno G D V Morales
RSRosa M O Sousa
Rosa M O Sousa
SPSoraya S Pereira
Soraya S Pereira
DADeborah Antunes
Deborah Antunes
FZFernando Berton Zanchi
Fernando Berton Zanchi
Malaria, caused by Plasmodium protozoa with Plasmodium falciparum as the most virulent species, continues to pose significant health challenges. Despite the availability of effective antimalarial drugs, the emergence of resistance has heightened the urgency for developing novel therapeutic compounds. In this study, we investigated the enoyl-ACP reductase enzyme of P. falciparum (PfENR) as a promising target for antimalarial drug discovery. Through a comprehensive analysis, we conducted a comparative evaluation of two lead compounds, LD1 (CID: 44405336, lead compounds 1) and LD2 (CID: 72703246, lead compounds 2), obtained from the PubChem/NCBI ligand database, to serve as reference molecules in the identification of potential derivatives using virtual screening assays. Among the newly identified candidates, Ligand 1 (LG1) and Ligand 2 (LG2) exhibited intriguing characteristics and underwent further investigation through docking and molecular dynamics simulations. Ligand 1 (LG1) demonstrated interactions similar to LD1, including hydrogen bonding with Asp218, while Ligand 2 (LG2) displayed superior binding energy comparable to LD1 and LD2, despite lacking hydrogen bonding interactions observed in the control compounds triclosan and its derivative 7-(4-chloro-2-hydroxyphenoxy)-4-methyl-2H-chromen-2-one (CHJ). Following computational validation using the MM/GBSA method to estimate binding free energy, commercially acquired LG1 and LG2 ligands were subjected to in vitro testing. Inhibition assays were performed to evaluate their potential as PfENR inhibitors alongside triclosan as a control compound. LG1 exhibited no inhibitory effects, while LG2 demonstrated inhibitory effects like triclosan. In conclusion, this study contributes valuable insights into developing novel antimalarial drugs by identifying LG2 as a potential ligand and employing a comprehensive approach integrating computational and experimental methodologies.

16 February 2022 in Revista Brasileira de Farmacognosia
Verified
Journal Article
Closed access
PDF file
LSLuís Fernando Souto
Luís Fernando Souto
GOGeorge Azevedo de Oliveira
George Azevedo de Oliveira
ASAntonio Jorge Ribeiro Da Silva
Antonio Jorge Ribeiro Da Silva

13 May 2022 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
TSTalia Iasmin Pereira da Silva
Talia Iasmin Pereira da Silva
NZNabia Azevedo Zeferino
Nabia Azevedo Zeferino
BMBruno Gildo Dalla Vecchia Morales
Bruno Gildo Dalla Vecchia Morales
GOGeorge Azevedo Reis de Oliveira
George Azevedo Reis de Oliveira
FZFernando Berton Zanchi
Fernando Berton Zanchi
Objetivo: Calcular e comparar a densidade de médicos/mil habitantes nos municípios de Rondônia em 2020 e verificar as divergências entre as fontes oficiais de dados de 2010 até 2020. Métodos: Estudo ecológico nos municípios de Rondônia utilizando as bases do DATASUS, do Conselho Federal de Medicina e do IBGE; a planilha Excel foi utilizada para tabulação e cálculos estatísticos; a ferramenta de geoprocessamento QGIS foi utilizada para interpolação dos dados geográfica com o método de Ponderação do Inverso das Distâncias. Resultados: Em Rondônia, há uma divergência de 500 médicos entre as bases do TABNET e do CFM e o município de Cacoal, no interior, possui a maior densidade no estado com 4,13 médicos/mil habitantes. A interpolação demonstra maior densidade médica às margens da principal rodovia que dá acesso ao estado (BR-364). Conclusão: Não é a capital, Porto Velho, que apresenta maior densidade de médicos/mil habitantes. O CFM sempre apresenta número de médicos maior que o TABNET.

1 January 2024 in Anais da Academia Brasileira de Ciências
Verified
Journal Article
Open access
PDF file
BMBruno G. Dalla Vecchia Morales
Bruno G. Dalla Vecchia Morales
JEJoseph Albert Medeiros Evaristo
Joseph Albert Medeiros Evaristo
GOGeorge A.R. DE Oliveira
George A.R. DE Oliveira
AGAna Fidelina G. Garay
Ana Fidelina G. Garay
JDJorge Javier A.R. Diaz
Jorge Javier A.R. Diaz
FZFernando Berton Zanchi
Fernando Berton Zanchi
Plasmodium falciparum is known to cause severe malaria, current treatment consists in artemisinin-based combination therapy, but resistance can lead to treatment failure. Knowledge concerning P. falciparum essential proteins can be used for searching new antimalarials, among these a potential candidate is shikimate dehydrogenase (SDH), an enzyme part of the shikimate pathway which is responsible for producing endogenous aromatic amino acids. SDH from P. falciparum (PfSDH) is unexplored by the scientific community, therefore, this study aims to establish the first protocol for active PfSDH expression. Putative PfSDH nucleotide sequence was used to construct an optimized expression vector pET28a+PfSDH inserted in E. coli BL21(DE3). As a result, optimal expression conditions were acquired by varying IPTG and temperature through time. Western Blot analysis was applied to verify appropriate PfSDH expression, solubilization and purification started with lysis followed by two-steps IMAC purification. Enzyme activity was measured spectrophotometrically by NADPH oxidation, optimal PfSDH expression occur at 0.1 mM IPTG for 48 hours growing at 37 °C and shaking at 200 rpm, recombinant PfSDH obtained after purification was soluble, pure and its physiological catalysis was confirmed. Thus, this study describes the first protocol for heterologous expression of PfSDH in soluble and active form.